The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats

Cardiovascular Diabetology

Volumn 9, Issue , 2010, Pages

  Liu, Que ^a   Adams, Lisa ^a   Broyde, Anatoly ^a   Fernandez, Rayne ^a   Baron, Alain D ^a   Parkes, David G ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AC 3174; CAPTOPRIL; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; UNCLASSIFIED DRUG; AC3174; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CARDIOTONIC AGENT; DRUG DERIVATIVE; PEPTIDE; VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; BODY WEIGHT; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE MASS; HYPERTENSION; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY INJURY; MALE; MONOTHERAPY; NONHUMAN; POSTPRANDIAL STATE; RAT; SALT INTAKE; SURVIVAL; SYSTOLIC BLOOD PRESSURE; ANIMAL; DRUG COMBINATION; DRUG EFFECT; HYPERGLYCEMIA; KIDNEY DISEASE; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RENOVASCULAR HYPERTENSION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; CAPTOPRIL; CARDIOTONIC AGENTS; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; HYPERGLYCEMIA; HYPERTENSION, RENAL; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; KIDNEY DISEASES; MALE; PEPTIDES; RATS; RATS, INBRED DAHL; SODIUM CHLORIDE, DIETARY; VENOMS;

EID: 77955106477     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-9-32     Document Type: Article

References (44)

1. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng Z, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC, Hong Y, , Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P. Members of the Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006, 113:e85-e151. 10.1161/CIRCULATIONAHA.105.171600, 16407573, Members of the Statistics Committee and Stroke Statistics Subcommittee.
2. Chobanian AV, . the National Committee The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). 2004, Bethesda, MD: National Institutes of Health, U.S. Department of Health and Human Services, NIH Publication No. 04-5230, the National Committee.
3. Ong KL, Cheung BMY, Man YB, Lau CP, Lam KSL. Prevalence, awareness treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007, 49:69-75. 10.1161/01.HYP.0000252676.46043.18, 17159087.
4. Lalande S, Johnson BD. Diastolic dysfunction: a link between hypertension and heart failure. Drugs Today 2008, 44:503-513. 10.1358/dot.2008.44.7.1221662, 2713868, 18806901.
5. Verma A, Solomon SD. Diastolic dysfunction as a link between hypertension and heart failure. Med Clin N Am 2009, 93:647-664. 10.1016/j.mcna.2009.02.013, 19427497.
6. Sciarretta S, Paneni F, Palano F, Chin D, Tocci G, Rubattu S, Volpe M. Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. Clin Sci 2009, 116:467-477. 10.1042/CS20080390, 19200056.
7. Sander GE, Giles TD. Diabetes mellitus and heart failure. Amer Heart Hosp J 2003, 1:273-280.
8. Reboldi G, Gentile G, Angeli F, Verdecchia P. Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Vasc Hlth Risk Manag 2009, 5:411-427.
9. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007, 117:24-32. 10.1172/JCI30076, 1716213, 17200703.
10. Nikolaidis LA, Sunil Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962-965. 10.1161/01.CIR.0000120505.91348.58, 14981009.
11. Kavianipour M, Ehlers MR, Malmberg K, Ronquist G, Ryden L, Gutniak WG. Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides 2003, 24:569-578. 10.1016/S0196-9781(03)00108-6, 12860201.
12. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT, Shannon RP. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004, 110:955-961. 10.1161/01.CIR.0000139339.85840.DD, 15313949.
13. Yu M, Moreno C, Hoagland KM, Dahly A, Ditter K, Mistry M, Roman RJ. Antihypertensive effects of glucagon-like peptide-1 in Dahl salt-sensitive rats. J Hypertension 2003, 21:1125-1135.
14. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin 4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004, 117:77-88. 10.1016/j.regpep.2003.10.028, 14700743.
15. Nielsen LL, Okerson T, Holcombe J, Hoogwerf B. Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes. J Diab Sci Tech 2008, 2:255-260.
16. Malone J, Trautmann M, Wilhelm K, Taylor K, Kendall DM. Exenatide once weekly for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2009, 18:359-367. 10.1517/13543780902766802, 19243286.
17. Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, Baron AD, Parkes D, Young AA. Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005, 146:2069-2076. 10.1210/en.2004-1349, 15618356.
18. Gardiner SM, March JE, Kemp PA, Bennett T. Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats. J Pharmacol Exp Ther 2006, 316:852-859. 10.1124/jpet.105.093104, 16221740.
19. Laguero KD, Stonehouse AH, Guss S, Landry J, Vu C, Parkes DG. Exenatide improves hypertension in a rat model of the metabolic syndrome. Metabolic Syndr Rel Disorders 2009, 7:327-334.
20. Hirata K, Kume S, Araki S, Sakaguchi M, Chin-Kanasaki M, Isshiki K, Sugimoto T, Nishiyama A, Koya D, Haneda M, Kashiwagi A, Uzu T. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun 2009, 380:44-49. 10.1016/j.bbrc.2009.01.003, 19150338.
21. Gutzwiller J, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, Gutmann H, Drewe J, Henzen C, Goeke B, Beglinger C. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004, 89:3055-3061. 10.1210/jc.2003-031403, 15181098.
22. Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006, 8:436-447. 10.1111/j.1463-1326.2006.00602.x, 16776751.
23. Moretto TJ, Milton DR, Ridge TD, MacConell LA, Okerson T, Wolka AM, Brodows RG. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008, 30:1448-1460. 10.1016/j.clinthera.2008.08.006, 18803987.
24. Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Amer J Hypertens 2009, 23:334-339.
25. Fujii N, Nozawa T, Igawa A, Kato B, Igarashi N, Nonomura M, Asanoi H, Tazawa S, Inoue M, Inoue H. Saturated glucose uptake capacity and impaired fatty acid oxidation in hypertensive hearts before development of heart failure. Am J Physiol Heart Circ Physiol 2004, 287:H760-766. 10.1152/ajpheart.00734.2003, 15031123.
26. Yoshida J, Yamamoto K, Mano T, Sakata Y, Nishikawa N, Nishio M, Ohtani T, Miwa T, Hori M, Masuyama T. AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure. Hypertens 2004, 43:686-691.
27. Sakata Y, Yamamotoa K, Manoa T, Nishikawaa N, Yoshida J, Miwa T, Hori M, Masuyama T. Temocapril prevents transition to diastolic heart failure in rats even if initiated after appearance of LV hypertrophy and diastolic dysfunction. Cardiovasc Res 2003, 57:757-765. 10.1016/S0008-6363(02)00722-8, 12618237.
28. Pinto YM, Paul M, Ganten D. Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovasc Res 1998, 39:77-88. 10.1016/S0008-6363(98)00077-7, 9764191.
29. Reaven GM, Twersky J, Chang H. Abnormalities of carbohydrate and lipid metabolism in Dahl rats. Hypertension 1991, 18:630-635.
30. Nishikimi T, Akimotob K, Wanga X, Moria Y, Tadokoroa K, Ishikawaa Y, Shimokawac H, Ono H, Matsuoka H. Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. J Hypertens 2004, 22:1787-1796. 10.1097/00004872-200409000-00024, 15311108.
31. Maric C, Sandberg K, Hinojosa-Laborde C. Glomerulosclerosis and tubulointerstitial fibrosis are attenuated with 17β-estradiol in the aging Dahl salt sensitive rat. J Am Soc Nephrol 2004, 15:1546-1556. 10.1097/01.ASN.0000128219.65330.EA, 15153565.
32. Hargrove DM, Kendall ES, Reynolds JM, Lwin AN, Herich JP, Smith PA, Gedulin BR, Flanagan SD, Jodka CM, Hoyt JA, McCowen KM, Parkes DG, Anderson CM. Biological activity of AC3174, a peptide analog of exendin-4. Reg Pept 2007, 141:113-119.
33. Dahl LK, Heine M, Tassinari L. Effects of chronic excess salt ingestion: evidence that genetic factors play an important role in susceptibility to experimental hypertension. J Exp Med 1962, 115:1173-1190. 10.1084/jem.115.6.1173, 2137393, 13883089.
34. Parkes D, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R, Chen K, Young A. Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev Res 2001, 53:260-267.
35. Kohara K, Brosnihan B, Ferrario CM. Angiotensin(1-7) in the spontaneously hypertensive rat. Peptides 1993, 14:883-891. 10.1016/0196-9781(93)90063-M, 8284265.
36. Timmers L, Henriques JPS, de Kleijn DPV, DeVries JH, Kemperman H, Steendijk P, Verlaan CWJ, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009, 53:501-510. 10.1016/j.jacc.2008.10.033, 19195607.
37. Mack CM, Moore CX, Jodka CM, Bhasvsar S, Wilson JK, Hoyt JA, Roan JL, Vu C, Laugero KD, Parkes DG, Young AA. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obesity 2006, 30:1332-1340.
38. van Heerebeek L, Somsen A, Paulus WJ. The failing diabetic heart: focus on diastolic left ventricular dysfunction. Curr Diab Rep 2009, 9:79-86. 10.1007/s11892-009-0014-9, 19192429.
39. Kashyap SR, DeFronzo RA. The insulin resistance syndrome: physiological considerations. Diab Vasc Dis Res 2007, 4:13-19. 10.3132/dvdr.2007.001, 17469039.
40. Shehata MF. Genetic and dietary salt contributors to insulin resistance in Dahl salt-sensitive (S) rats. Cardiovasc Diabetol 2008, 7:7. 10.1186/1475-2840-7-7, 2365939, 18397529.
41. Shehata MF. Important genetic checkpoints for insulin resistance in salt-sensitive (S) Dahl rats. Cardiovasc Diabetol 2008, 7:19. 10.1186/1475-2840-7-19, 2459151, 18570670.
42. Young AA. Glucagon-like peptide-1, exendin and insulin sensitivity. Insulin resistance and insulin resistance syndrome 2002, Chapter 14:235-262. New York: Taylor and Francis, Hansen B, Shafir E.
43. Ideishi M, Miura S, Sakai T, Maeda H, Kinoshita A, Sasaguri M, Jimi S, Arakawa K. Comparative effects of an angiotensin-converting enzyme inhibitor and an angiotensin II antagonist in Dahl rats. Blood Pressure 1994, 3(Suppl 5):99-104.
44. Crofton JT, Ota M, Share L. Role of vasopressin, the renin-angiotensin system and sex in Dahl salt-sensitive hypertension. J Hypertens 1993, 11:1031-1038. 10.1097/00004872-199310000-00005, 8258666.